The purpose of this database study is to assess if Arepanrix™ vaccination during the 2009 pandemic was associated with an increased risk of multiple sclerosis (MS) in Manitoba, Canada.

Start Date01 Aug 2014

Sponsor / Collaborator

University of Manitoba

[+1]

NCT01394614 / CompletedNot ApplicableIIT

Risk of Narcolepsy Associated With Administration of Inactivated Adjuvanted (AS03) A/H1N1 Pandemic Influenza Vaccine in Quebec

The goal of the study is to assess the risk of occurrence of narcolepsy following the administration of inactivated (AS03) adjuvanted A/H1N1 pandemic influenza vaccine in the province of Quebec, Canada, using different case definitions and time intervals to disease onset, while controlling for potential confounding variables such as age, gender, season and, when possible, A/H1N1 pandemic influenza infection. Another aim is to describe the epidemiology and clinical features of narcolepsy cases with onset during the period January 1st, 2009 to December 31, 2010 in the population of Quebec.

Start Date01 Jun 2011

Sponsor / Collaborator

Hopital du Sacré-Coeur de Montréal

[+1]

NCT01161160 / CompletedPhase 2

An Observer-blind Safety and Immunogenicity Study of GSK Biologicals' A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340272A in Children 3 to Less Than 10 Years Old

This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.

Start Date01 Jul 2010

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Pandemic influenza vaccine (H1N1)(GlaxoSmithKline Biologicals SA)

100 Translational Medicine associated with Pandemic influenza vaccine (H1N1)(GlaxoSmithKline Biologicals SA)

100 Patents (Medical) associated with Pandemic influenza vaccine (H1N1)(GlaxoSmithKline Biologicals SA)

106

Literatures (Medical) associated with Pandemic influenza vaccine (H1N1)(GlaxoSmithKline Biologicals SA)

01 Dec 2022·Immunity & Ageing

Poly-γ-glutamic acid/Alum adjuvanted pH1N1 vaccine-immunized aged mice exhibit a significant increase in vaccine efficacy with a decrease in age-associated CD8+ T cell proportion in splenocytes

Article

Author: Poo, Haryoung ; Kwak, Chaewon ; Kim, Jaemoo ; Yang, Jihyun

AbstractBackgroundHighly contagious respiratory diseases caused by viral infections are a constantly emerging threat, particularly the elderly with the higher risk of developing serious complications. Vaccines are the best strategy for protection against influenza-related diseases. However, the elderly has lower vaccine efficacy than young population and the age-driven decline of the influenza vaccine efficacy remains unresolved.ObjectivesThis study investigates the effect of an adjuvant, poly-γ-glutamic acid and alum (PGA/Alum) on vaccine efficacy in aged mice (18-months) and its mechanism is investigated using ovalbumin as a model antigen and a commercial pandemic H1N1 (pH1N1) flu vaccine. Antigen trafficking, dendritic cell (DC) activation, and the DC-mediated T cell activation were analyzed via in vivo imaging and flow cytometry. Antigen-specific humoral and cellular immune responses were evaluated in sera and splenocytes from the vaccinated mice. Also, we analyzed gene expression profiles of splenocytes from the vaccinated mice via single-cell transcriptome sequencing and evaluated the protective efficacy against pH1N1 virus challenge.ResultsAged mice had lower antigen trafficking and DC activation than younger mice (6-weeks), which was ameliorated by PGA/Alum with increased antigen uptake and DC activation leading to improved antigen-specific IFN-γ+CD8+ T lymphocyte frequencies higher in the vaccinated aged mice, to a similar extent as PGA/Alum adjuvanted vaccine-immunized young mice. The results of single-cell transcriptome sequencing display that PGA/Alum also reduced the proportion of age-associated CD8+ T cell subsets and gene levels of inhibitory regulators in CD8+ T cells, which may play a role in the recovery of CD8+ T cell activation. Finally, PGA/Alum adjuvanted pH1N1 vaccine-immunized aged mice were completely protected (100% survival) compared to aged mice immunized with vaccine only (0% survival) after pH1N1 virus challenge, akin to the efficacy of the vaccinated young mice (100% survival).ConclusionsPGA/Alum adjuvanted pH1N1 vaccine-immunized aged mice showed a significant increase in vaccine efficacy compared to aged mice administered with vaccine only. The enhanced vaccine efficacy by PGA/Alum is associated with significant increases of activation of DCs and effector CD8+ T cells and a decrease in age-associated CD8+ T cell proportion of splenocytes. Collectively, PGA/Alum adjuvanted flu vaccine may be a promising vaccine candidate for the elderly.

01 Feb 2020·VaccineQ3 · MEDICINE

Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods

Q3 · MEDICINE

Article

Author: Thedi Ziegler ; Henna Päkkilä ; Ritva Syrjänen ; Matti Waris ; Ilkka Julkunen ; Laura Kakkola ; Tero Soukka ; Anna Kazakova

Influenza A viruses continue to circulate throughout the world as yearly epidemics or occasional pandemics. Influenza infections can be prevented by seasonal multivalent or monovalent pandemic vaccines. In the present study, we describe a novel multiplex microarray immunoassay (MAIA) for simultaneous measurement of virus-specific IgG and IgM antibodies using Pandemrix-vaccinated adult sera collected at day 0 and 28 and 180 days after vaccination as the study material. MAIA showed excellent correlation with a conventional enzyme immunoassay (EIA) in both IgG and IgM anti-influenza A antibodies and good correlation with hemagglutination inhibition (HI) test. Pandemrix vaccine induced 5-30 fold increases in anti-H1N1pdm09 influenza antibodies as measured by HI, EIA or MAIA. A clear increase in virus-specific IgG antibodies was found in 93-97% of vaccinees by MAIA and EIA. Virus-specific IgM antibodies were found in 90-92% of vaccinees by MAIA and EIA, respectively and IgM antibodies persisted for up to 6 months after vaccination in 55-62% of the vaccinees. Pandemic influenza vaccine induced strong anti-influenza A IgG and IgM responses that persisted several months after vaccination. MAIA was demonstrated to be an excellent method for simultaneous measurement of antiviral IgG and IgM antibodies against multiple virus antigens. Thus the method is well suitable for large scale epidemiological and vaccine immunity studies.

01 Aug 2019·Pediatric Infectious Disease JournalQ4 · MEDICINE

What We Need to Know to be Ready for the Next Pandemic

Q4 · MEDICINE

Review

Author: Lambert, Paul-Henri ; Black, Steven ; Edwards, Kathryn

After the initial identification of the H1N1 pandemic influenza strain in Mexico in April 2009 and its subsequent global spread, several monovalent influenza vaccines were developed as part of the pandemic response. Three of these vaccines, Pandemrix, Arepanrix and Focetria were adjuvanted. One of these, the AS03-adjuvanted Pandemrix vaccine, was primarily used in Europe. Following widespread Pandemrix vaccine administration in Scandinavia, an increased risk of narcolepsy was noted in observational studies. Subsequently, this increased risk was also reported in other European countries as well. In contrast, studies from Canada of a similar AS03-adjuvanted vaccine, Arepanrix, did not demonstrate a similar increased risk of narcolepsy. No studies have identified an increased risk of narcolepsy following the MF59-adjuvanted Focetria vaccine. For many potential pandemic influenza strains, adjuvants might be required to solicit a protective immune response. Thus, it is critical that we understand the nature of the association between adjuvanted vaccine receipt and narcolepsy. Here, we present a potential hypothesis for narcolepsy seen during the 2009 H1N1 pandemic in AS03-adjuvanted influenza vaccine recipients.

News (Medical) associated with Pandemic influenza vaccine (H1N1)(GlaxoSmithKline Biologicals SA)

19 May 2023

·www.fiercebiotech.com

FDA committee backs Pfizer's RSV shot for maternal population, though safety concerns remain

The FDA is set to make a decision for Abrysvo in the maternal population by Aug. 21. Pfizer’s RSV shot has won the support of an FDA advisory committee for use in pregnant people to protect infants, but lingering concerns remain from a few members that couldn’t back the vaccine’s safety. The Vaccines and Related Biological Products Advisory Committee voted on both the safety and efficacy of Pfizer’s Abrysvo immunization to protect infants aged birth through 6 months from RSV lower respiratory tract disease and severe RSV disease when administered during the second or third trimester of pregnancy. While Abrysvo sailed through the efficacy portion—securing a unanimous 14-0 favorable vote—the committee was more divided on safety data, with 10 members voting in favor of recommending approval and four in opposition. “I felt that there was too much uncertainty, based on the data that were presented and discussed today,” said Holly Janes, Ph.D., a biostatistician and professor for Fred Hutchinson Cancer Center’s vaccine and infectious disease division and public health sciences division, one of the four who did not vote in favor on the safety measure. The debate over safety was somewhat surprising after FDA documents filed earlier this week didn’t flag any significant safety concerns. The documents examined data submitted by Pfizer from five studies across 4,144 participants that were submitted for consideration with the vaccine's biologics license application. A double-blind phase 3 study conducted across 18 countries was at the heart of the committee’s conversation. The most commonly reported safety events from the phase 3 trial were pain at the injection site and fatigue in shot recipients. Both the FDA and Pfizer agreed that Abrysvo’s adverse event profile was favorable. One maternal death was recorded in the treatment arm of the study, but the death was due to postpartum hemorrhage and hypovolemic shock that was determined unlikely to be related to the study. The concern came when looking at safety data for the infants. The phase 3 study showed a 1% higher rate of preterm births in the vaccine arm at a rate of 5.7% preterm birth compared with 4.7% in the placebo group. One infant was born preterm at 36 weeks and five days, 86 days after the maternal vaccination. While this was considered related to receiving the shot, the child had a normal birth outcome and there were no complications, according to the FDA. Both Pfizer and the FDA said the numerical imbalance didn’t appear to be statistically significant, but many committee members took issue with the data. Janes said she voted no because she was concerned that as the vaccine was rolled out to a broader, more diverse population, there was a potential the risk of preterm birth could increase, and alongside it, the chance of a low birth weight. “If I compare the very small risk of earlier birth with the almost certain risk of getting RSV and a very high risk of ending up in the hospital, I have to say that the risk is much greater if we don't give the vaccine than if we do,” pediatric allergist-immunologist Jay Portnoy, M.D., said. “So that's why I voted yes.” “It’s clear it’s a pretty controversial topic,” Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research at the FDA, said. Paul Offit, M.D., director of the vaccine education center at the Children’s Hospital of Pennsylvania, was particularly hung up on the safety data, citing GSK's decision last year to halt a maternal RSV candidate in 2021 over prematurity concerns. The pharma has yet to restart its work in the area. “Was this adequate in terms of reassuring one that what was seen with the GSK vaccine is not going to be seen here?” Offit asked, saying that he personally didn’t believe it was sufficient, which was why he voted “no” for the safety half of the vote. “That company abandoned that program, and those decisions are never made lightly,” he said of GSK. The same committee also reviewed and endorsed GSK’s rival RSV vaccine candidate Arexvy, which has since become the first shot to be approved in the older population. Pfizer has also requested approval of Abrysvo in the older population, which was examined at a similar advisory meeting in February. The committee was less divided when discussing the efficacy data for the maternal population. Pfizer demonstrated that Abrysvo was effective at preventing RSV lower respiratory tract disease and severe RSV disease in infants when administered at 24 to 36 weeks gestation. The shot was 82% effective at preventing lab-confirmed severe medically attended lower respiratory tract illness caused by RSV at 90 days after birth and 69% effective in protecting at 180 days. At preventing lab-confirmed disease altogether, Abrysvo was 57% effective through 90 days after birth. This measure was “clinically meaningful,” according to Pfizer, but didn’t meet the study's primary endpoint. The study’s secondary endpoints found Abrysvo was 68% effective at preventing RSV-associated hospitalizations through 90 days post-birth and 57% effective through 180 days. Pfizer also examined the vaccine’s efficacy against RSV-associated medically attended lower respiratory tract illness, finding it was 45% effective and 41% effective through 210 and 360 days after birth, respectively. This effect didn’t last beyond 360 days after birth. During the presentation, Pfizer representatives said Abrysvo has the potential to reduce global infant mortality due to RSV if approved, a claim underscored by the fact that at least one infant died from respiratory illness due to RSV in the placebo group in one of Pfizer's studies. This is the second advisory meeting in recent months centering on Pfizer’s bivalent vaccine. Abrysvo was endorsed by the same committee in February for preventing lower respiratory tract disease caused by RSV in older adults, although the FDA flagged some safety concerns such as Guillain-Barré syndrome. A decision for the vaccine’s use in the older population is expected by May 31. The FDA is then slated to make a decision for Abrysvo for the maternal population by Aug. 21. The vaccine was granted priority-review designation earlier this year. If approved, Abrysvo would be the first vaccine to protect against the virus in infants. Pfizer faces rival AstraZeneca and Sanofi’s long-acting antibody nirsevimab, which is administered after birth but could also win approval this year.

VaccinePhase 3Priority ReviewDrug ApprovalClinical Result

03 May 2023

·medcitynews.com

First FDA Approval of an RSV Vaccine Goes to GSK

The FDA has approved the first vaccine for respiratory syncytial virus, a pathogen that typically circulates in the fall and winter months, leading to serious and potentially deadly infections, particularly in infants and the elderly. The Wednesday approval of the vaccine, known in development as RSVPreF3 OA, covers the prevention of RSV infection in adults age 60 and older. GSK will market its new product under the brand name “Arexvy.” The British pharmaceutical giant said it plans to launch its new vaccine before the 2023/2024 RSV season. In April, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of the GSK RSV vaccine. A decision in Europe is expected in coming months. “Our focus now is to ensure eligible older adults in the U.S, can access the vaccine as quickly as possible and to progress regulatory review in other countries,” GSK Chief Scientific Officer Tony Wood said in a prepared statement. Though RSV can infect anyone, people with strong immune systems usually fight off the virus experiencing symptoms no more serious than those of the common cold. But in infants who have narrow breathing passages and immune systems that are still developing, RSV infection can become deadly. The infection is also serious in the elderly, who may have weaker immune systems or underlying conditions that put them at higher risk of complications. RSV infection can lead to lower respiratory tract disease, such as pneumonia and bronchiolitis. According to the Centers for Disease Control and Prevention, each year RSV leads to an estimated 60,000 to 160,000 hospitalizations in those 65 and older, and an estimated 6,000 to 10,000 deaths in that age group. Arexvy is designed to spark an immune response to RSV F, a protein on the surface of the virus that it uses to fuse to and enter a cell. The vaccine contains an engineered part of a prefusion form of RSV F (RSVPref3). This antigen is combined with a proprietary GSK adjuvant, an ingredient that boosts the immune response. Arexvy is being evaluated in an ongoing placebo-controlled Phase 3 study enrolling about 25,000 participants in the U.S. and around the world. The study is designed to assess a single dose of the GSK vaccine. The study will follow participants for two additional RSV seasons to assess how long the shot’s effects last as well as the safety and efficacy of repeat vaccination. The FDA based its approval on data from the first RSV season. Those results showed the vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6%. Results also showed the shot reduced the risk of developing severe lower respiratory tract disease by 94.1%. GSK first reported those Phase 3 results last October. In the clinical trial results so far, the FDA said the most commonly reported side effects in a subset of those in the vaccination group included injection site pain, fatigue, muscle pain, headache, and pain and joint stiffness. The agency also noted that across the entire study population, atrial fibrillation was reported within 30 days in 10 participants who received Arexvy and four who were injected with a placebo. More serious problems may be associated with interactions with other vaccines. In one other study testing Arexvy in those 60 and older, the FDA said some participants received the GSK vaccine at the same time they received an approved influenza vaccine. Two of those participants developed acute disseminated encephalomyelitis (ADEM), a rare type of brain and spinal cord inflammation. One of those who developed this type of inflammation died. In yet another study testing Arexvy in older adults, a participant developed Guillain-Barré syndrome, a rare condition in which the body’s immune system damages nerve cells, causing muscle weakness and even paralysis. The FDA is requiring GSK to conduct a post-marketing study to assess the risk signs for both Guillain-Barré syndrome and ADEM. The FDA also said GSK has committed to assess atrial fibrillation in the post-marketing research, though the agency is not requiring the company to do so. Other companies are on GSK’s heels with their own RSV vaccines. Pfizer’s RSV vaccine for adults is still under FDA review. Moderna has said it expects to submit an application for its RSV vaccine in the first half of this year. Johnson & Johnson formally withdrew from the RSV vaccine race in March. Though J&J’s shot led to strong results in mid-stage testing, the company stopped a Phase 3 study as part of what it described as a reprioritization of assets. Image by GSK

Phase 3VaccineClinical ResultDrug Approval

13 Oct 2022

·www.reuters.com

RSV vaccine race heats up with highly effective GSK shot

LONDON, Oct 13 (Reuters) - Data unveiled on Thursday showed GSK's (GSK.L) respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults. RSV is a leading cause of pneumonia in toddlers and the elderly, causing thousands of hospitalisations and deaths each year, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine. The trial, which involved roughly 25,000 adults aged 60 and over, showed the vaccine was 94.1% effective against severe lower respiratory tract disease associated with an RSV infection, the British drugmaker said. "These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research," said Tony Wood, GSK Chief Scientific Officer, in a statement. GSK's shares rose about 1.7% in early trading. The company is a key player in the race to develop a safe and effective RSV vaccine, which, if approved, is expected to generate billions in sales for its maker. Regulatory submissions are planned later this year. If approved, Jefferies analysts have forecast $2.5 billion in global RSV vaccine peak sales in older adults for GSK. GSK said in June the trial had yielded statistically significant results for the shot, but on Thursday gave details about the performance of the vaccine. U.S. drugmaker Pfizer (PFE.N) in August disclosed positive Phase III data on its rival RSV vaccine in older adults. Efficacy against RSV-associated lower respiratory tract illness with two or more symptoms was 66.7%, while efficacy against severe disease defined by three or more symptoms was 85.7%, the company said. Given different definitions of the trial endpoints across the GSK and Pfizer studies, a direct comparison of efficacy is difficult, Morgan Stanley analysts said on Thursday. "That said, the GSK data do look strong relative to that presented by Pfizer," they added. In trial participants with pre-existing conditions, the GSK vaccine was shown to be 94.6% effective, while in adults aged 70 to 79 it was 93.8% effective, the company said. The performance of Pfizer's vaccine across key subgroups, possible differences in safety and tolerability between the GSK and Pfizer shot, as well as any early signs of how durable the protection for either shot is, will be the key focus of presentations from both drugmakers at a medical conference next week, Jefferies analysts said. A late-stage readout on Johnson & Johnson's (JNJ.N) RSV vaccine in older adults is also expected by the end of 2022, while an interim look at Moderna's (MRNA.O) rival shot's Phase III data is also anticipated this winter. Our Standards: The Thomson Reuters Trust Principles.

Vaccine

100 Deals associated with Pandemic influenza vaccine (H1N1)(GlaxoSmithKline Biologicals SA)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB02	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Preclinical	EU	GlaxoSmithKline Biologicals SA	23 Mar 2010
Influenza, Human	Preclinical	NO	GlaxoSmithKline Biologicals SA	23 Mar 2010
Influenza, Human	Preclinical	IS	GlaxoSmithKline Biologicals SA	23 Mar 2010
Influenza, Human	Preclinical	LI	GlaxoSmithKline Biologicals SA	23 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01003418 (CTgov)	Phase 2	Influenza, Human	8	GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine+Prevenar+Infanrix™-IPV/Hib (GSK2340272A Group 1)	vbuencywlg(bqaeqyqfti) = ceeodyxcwh ffssvactdr (pooqgqrmvg, cetwrzmsew - oabyxxoych) View more	-	15 Feb 2019
				GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine+Prevenar+Infanrix™-IPV/Hib (GSK2340272A Group 2)	vbuencywlg(bqaeqyqfti) = qeylgwajpc ffssvactdr (pooqgqrmvg, ypapaqlrqg - owgbwdgzmi) View more
NCT00992511 (CTgov)	Phase 3	Influenza, Human	300	GSK investigational vaccine GSK2340272A (GSK2340272A New 1D Group)	ptmrntiobn(zewzwozczs) = jnbgjlgwqn bidgmydieg (zouirauvrc, imztikqzal - jrcepghbub) View more	-	31 Jan 2019
				GSK investigational vaccine GSK2340272A (GSK2340272A New 2D Group)	ptmrntiobn(zewzwozczs) = xkyighchfn bidgmydieg (zouirauvrc, erywvhmzte - stdrilvpzv) View more
NCT00975884 (CTgov)	Phase 3	Influenza, Human	312	GSK investigational vaccine GSK2340272A (GSK2340272A (D21) GROUP)	kwwhgurqbe(pdwupjkxoa) = mxtwymaefj idyncaerwh (tlztpdlcxw, vqxkonmpbq - clbsiqsdri) View more	-	28 Jan 2019
				GSK investigational vaccine GSK2340272A (GSK2340272A (M6) GROUP)	kwwhgurqbe(pdwupjkxoa) = xhlchtiwsc idyncaerwh (tlztpdlcxw, klyeevyzgr - qjxurdzfod) View more
NCT00989612 (CTgov)	Phase 2	Influenza, Human	100	Influenza investigational vaccine GSK2340274A	dsflfpojxl(vxuciketln) = johtmovlsw dvijkiztdx (euvcxhdiij, wzrqszabhq - amchqyotoh) View more	-	16 Jan 2019
NCT00951041 (CTgov)	Phase 2	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	yfugfihdga(jszvqywkrv) = oewmlkyekt mjuphbstuf (ejeznznhjk, cfxfkchwaw - fixnzrejwf) View more	-	26 Nov 2018
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	yfugfihdga(jszvqywkrv) = qmcmlwhcvs mjuphbstuf (ejeznznhjk, ivqoauxnjn - gomwzadizp) View more
NCT00968526 (CTgov)	Phase 3	Influenza, Human	240	GSK investigational vaccine GSK2340272A (GSK2340272A 1D Group)	wdtsmnzajr(jeobqgcxdq) = xtcipyagtq jlxztxatgl (vriaagyual, bunkofmpau - nmebemmloh) View more	-	18 Sep 2018
				GSK investigational vaccine GSK2340272A (GSK2340272A 2D Group)	wdtsmnzajr(jeobqgcxdq) = wbnleecwfo jlxztxatgl (vriaagyual, axsheojbso - obphsaxfkp) View more
NCT00979407 (CTgov)	Phase 3	Influenza, Human	336	Influenza vaccine GSK2340272A (GSK2340272A GROUP)	wzrfencdki(exakybwxpn) = hgnciwqrxn pockngpvfy (logxiafqiv, iwmlpyxrus - xcwwyschbb) View more	-	06 Aug 2018
				Influenza vaccine GSK2340274A (GSK2340274A GROUP)	wzrfencdki(exakybwxpn) = thsgixiegx pockngpvfy (logxiafqiv, zvtejzeglo - oovtghbfww) View more
NCT00989287 (CTgov)	Phase 3	Influenza, Human	131	GSK2340272A (GSK2340272A Group)	ogzqhtdzbz(ftwxgziyuu) = dfmivfxcxo pfmuaeeeiw (ywqnmceqhd, soncbkajod - fwvtnqjcyn) View more	-	05 Mar 2018
				GSK2340269A (GSK2340269A Group)	ogzqhtdzbz(ftwxgziyuu) = gryykvwaoi pfmuaeeeiw (ywqnmceqhd, lmffooraaw - jprzjjqfdg) View more
NCT00964158 (CTgov)	Phase 3	Influenza, Human	210	GSK2340272A vaccine (GSK2340272A Group)	oweuocxzqf(aruoksjdvp) = qpzluwpjvy qcwexjnslb (bfrytbrbsw, dtyymoxrgp - ayktkyabdf) View more	-	19 Feb 2018
				GSK2340272A (3-5Y) (GSK2340272A (3-5Y) Group)	dsteimjgzy(ldkfdnqpqe) = vvsywuzvqu nlskritlol (xykytiqgle, dpisupcvjk - dquodmtvzm) View more
NCT00968539 (CTgov)	Phase 3	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	xepvrrzwfz(fbsvecmdhm) = stztqlvpkz ruorawyztp (ugchejzust, bjugkdpezw - hntmvieirz) View more	-	18 Dec 2017
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	davpcbwjhp(jhmbkzbzjp) = sncztibjzx rwqipewmjo (ajislwubst, mszwgmjnnf - bxfcefzlku) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis